Results showed that the average number of MCTs delegates said that they had personally diagnosed in the last year to be just 7.03. This is in contrast to research that shows, on average, vets will diagnose at least one case per month, or 12 a year (KG Marketsense UK and DE market assessment and EBC-46 product concept test, 2016), highlighting the need for increased awareness of the most common form of canine cutaneous neoplasia.
MCTs are the most common form of skin cancer in dogs, accounting for up to 21 percent of skin cancer cases. Primarily a disease of older dogs, the incidence of MCTs is highest in dogs aged 6 to 10 years old with predisposition in some of the UK’s most popular breeds such as Labradors, French Bulldogs, Staffordshire Bull Terriers and Golden Retrievers.
To help vets and pet owners identify skin masses, Virbac have created a range of resources which can be found on the Virbac website.
Vets are also able to learn more about the latest medical treatment for canine mast cell tumours, Stelfonta. Until now surgical removal of the tumour has been the standard of care, but surgery can pose challenges for the veterinary surgeon, such as the accessibility of the tumour in order to obtain sufficient margins and anaesthetic risks, particularly in senior and brachycephalic pets. Seventy-seven percent of delegates at London Vet Show said they were either likely or very likely to use Stelfonta on their next mast cell tumour case.
The lucky winner of the stand competition was Jane Hill of Bay Vets who won £1,000 of shopping vouchers.
For more information on Stelfonta, or any of the other products in the Virbac portfolio, please speak to your Virbac Territory Manager.